New Bicistronic TALENs Greatly Improve Genome Editing

• Published in: Current protocols in stem cell biology Vol. 52; no. 1; p. e104
• Main Authors: Martín-Fernández, José María, Fleischer, Aarne, Vallejo-Diez, Sara, Palomino, Esther, Sánchez-Gilabert, Almudena, Ruiz, Raúl, Bejarano, Yazmine, Llinàs, Pere, Gayá, Antoni, Bachiller, Daniel
• Format: Journal Article
• Language: English
• Published: United States 01.03.2020
• Subjects: genome editing; FACS selection; bicistronic transcription activator-like effector nuclease; MACS selection; TALENs
• ISSN: 1938-8969
• DOI: 10.1002/cpsc.104

Genome editing has become one of the most powerful tools in present-day stem cell and regenerative medicine research, but despite its rapid acceptance and widespread use, some elements of the technology still need improvement. In this unit, we present data regarding the use of a new, more efficient type of transcription activator-like effector nuclease (TALEN) for gene editing. Our group has generated bicistronic genes in which classical TALEN coding sequences are linked by 2A elements to different reporter molecules, such as fluorochromes (TALEN-F) or membrane receptors (TALEN-M). This structure results in two proteins transcribed from the same transcript, of which the second (the reporter) can be used as the target for selection by fluorescence-assisted cell sorting (FACS) or magnetic-activated cell sorting (MACS). The application of these new TALEN genes allows a rapid enrichment of cells in which both members of the TALEN pair are active, thus eliminating the need for lengthy selection in culture and laborious characterization of a large number of clones. © 2020 by John Wiley & Sons, Inc. Basic Protocol 1: Generation of new TALENs Basic Protocol 2: Genome editing using TALEN-F Alternate Protocol 1: Generation of TALEN-M Support Protocol 1: mRNA in vitro transcription (IVT) of TALEN-T2A-reporter expression vector Alternate Protocol 2: Editing of primary T cells using TALEN-M Basic Protocol 3: Verifying gene editing Support Protocol 2: Rapid expansion protocol for edited T-cells.